Literature DB >> 9988186

Pathogenesis of experimental Ebola virus infection in guinea pigs.

B M Connolly1, K E Steele, K J Davis, T W Geisbert, W M Kell, N K Jaax, P B Jahrling.   

Abstract

The subtype Zaire of Ebola (EBO) virus (Mayinga strain) was adapted to produce lethal infections in guinea pigs. In many ways, the disease was similar to EBO infections in nonhuman primates and humans. The guinea pig model was used to investigate the pathologic events in EBO infection that lead to death. Analytical methods included immunohistochemistry, in situ hybridization, and electron microscopy. Cells of the mononuclear phagocyte system, primarily macrophages, were identified as the early and sustained targets of EBO virus. During later stages of infection, interstitial fibroblasts in various tissues were infected, and there was evidence of endothelial cell infection and fibrin deposition. The distribution of lesions, hematologic profiles, and increases in serum biochemical enzymes associated with EBO virus infection in guinea pigs was similar to reported findings in experimentally infected nonhuman primates and naturally infected humans.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9988186     DOI: 10.1086/514305

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  125 in total

1.  Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody.

Authors:  Paul W H I Parren; Tom W Geisbert; Toshiaki Maruyama; Peter B Jahrling; Dennis R Burton
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

2.  Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.

Authors:  J Brian Kimble; Delphine C Malherbe; Michelle Meyer; Bronwyn M Gunn; Marcus M Karim; Philipp A Ilinykh; Mathieu Iampietro; Khaled S Mohamed; Surendra Negi; Pavlo Gilchuk; Kai Huang; Yuri I Wolf; Werner Braun; James E Crowe; Galit Alter; Alexander Bukreyev
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

3.  Ebola virus transmission in guinea pigs.

Authors:  Gary Wong; Xiangguo Qiu; Jason S Richardson; Todd Cutts; Brad Collignon; Jason Gren; Jenna Aviles; Carissa Embury-Hyatt; Gary P Kobinger
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

4.  Evaluation of perceived threat differences posed by filovirus variants.

Authors:  Jens H Kuhn; Lori E Dodd; Victoria Wahl-Jensen; Sheli R Radoshitzky; Sina Bavari; Peter B Jahrling
Journal:  Biosecur Bioterror       Date:  2011-11-09

Review 5.  Filovirus vaccines.

Authors:  Steven B Bradfute; John M Dye; Sina Bavari
Journal:  Hum Vaccin       Date:  2011-06-01

6.  C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans.

Authors:  Carmen P Alvarez; Fátima Lasala; Jaime Carrillo; Oscar Muñiz; Angel L Corbí; Rafael Delgado
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

7.  Antigen capture enzyme-linked immunosorbent assay for specific detection of Reston Ebola virus nucleoprotein.

Authors:  Tetsuro Ikegami; Masahiro Niikura; Masayuki Saijo; Mary E Miranda; Alan B Calaor; Marvin Hernandez; Luz P Acosta; Daria L Manalo; Ichiro Kurane; Yasuhiro Yoshikawa; Shigeru Morikawa
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

8.  Advanced antisense therapies for postexposure protection against lethal filovirus infections.

Authors:  Travis K Warren; Kelly L Warfield; Jay Wells; Dana L Swenson; Kelly S Donner; Sean A Van Tongeren; Nicole L Garza; Lian Dong; Dan V Mourich; Stacy Crumley; Donald K Nichols; Patrick L Iversen; Sina Bavari
Journal:  Nat Med       Date:  2010-08-22       Impact factor: 53.440

9.  Humanized Mice--A Neoteric Animal Disease Model for Ebola Virus?

Authors:  Joseph Prescott; Heinz Feldmann
Journal:  J Infect Dis       Date:  2015-11-17       Impact factor: 5.226

10.  Pathophysiology of Ebola Virus Infection: Current Challenges and Future Hopes.

Authors:  Andrea Rivera; Ilhem Messaoudi
Journal:  ACS Infect Dis       Date:  2015-03-30       Impact factor: 5.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.